Recent SEC filings
Insider and ownership filing tracker
Form 4 reports insider transactions. Schedule 13D and 13G filings report certain significant ownership positions. 13F reports institutional holdings when filed by an investment manager. Always open the original filing for context.
Company and financial overview
This is a data-generated overview, not a published Rithvik Chethan research rating. Figures use the latest usable company filing and may differ from vendor-calculated trailing metrics.
Financial performance charts
Annual values from SEC filings. Free cash flow is calculated as operating cash flow less capital expenditures.
Upcoming catalyst timeline
Review the Earnings tab for the expected date and estimates.
FORM 4
EMA, RSI, MACD, volume, structure, and key levels update after a completed daily candle.
How the research score works
The overall score is a weighted research judgment covering business quality, fundamental strength, growth catalysts, valuation, technical condition, and downside risk. A high score does not eliminate risk, and a low score does not guarantee poor performance.
Company overview
Altria sells cigarettes and other tobacco products in the United States, primarily through its Marlboro brand, while investing in smoke free alternatives and holding a minority equity stake in a major beverage company.
Business model
The company earns revenue primarily from cigarette sales, a business facing steady long term volume decline offset partially by pricing power, along with smaller and growing smoke free product revenue streams.
Growth drivers
- Pricing power offsetting cigarette volume decline
- Smoke free product portfolio expansion
- Cost efficiency initiatives supporting margins
- Dividend focused capital return to shareholders
Competitive position
Altria's dominant position in the US cigarette market through Marlboro gives it substantial pricing power, though its smoke free product transition has been less successful than some international tobacco peers.
Risks
Long term cigarette volume decline is a structural headwind that pricing alone cannot fully offset indefinitely, regulatory risk around tobacco and nicotine products continues to evolve, and smoke free product execution has faced challenges relative to competitors.
Valuation
Altria trades at a low multiple typical of declining volume tobacco companies, with its high dividend yield being the primary appeal for income focused investors rather than growth potential.
Final view
Altria's structural cigarette volume decline makes this primarily an income oriented holding rather than a growth story. My view is cautious on long term prospects, with smoke free product execution being the key factor that could change that outlook.
Overall rating: 54/100
This website and its analysis are provided for educational and informational purposes only. Nothing on this site constitutes financial, investment, legal, or tax advice, or an offer to buy or sell any security. Market data is provided by Finnhub and other third-party sources and may be delayed, incomplete, or inaccurate. The author may hold positions in securities discussed, and opinions may change without notice. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial professional before making investment decisions.